FCAM
VRTX icon

F&C Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

F&C Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		$1.71M Buy
24,178
+7,529
+45% +$596K 0.02% 477
2013
Q4 		$1.24M Buy
16,649
+1,665
+11% +$116K 0.02% 518
2013
Q3 		$1.14M Buy
+14,984
New +$1.19M 0.01% 534

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

F&C Asset Management's VRTX Position: Q1 2014 in Review

F&C Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 45% in Q1 2014, buying an estimated $596K and bringing the position to 24,178 shares worth $1.71M. The position accounts for 0.02% of the portfolio, ranked #477.

F&C Asset Management first reported a position in VRTX in Q3 2013 and has held it in 3 quarters since. 395 funds tracked by Wall St. Rank hold VRTX as of Q1 2014.

  • F&C Asset Management held 24,178 shares of Vertex Pharmaceuticals worth $1.71M as of Q1 2014.
  • F&C Asset Management bought 7,529 Vertex Pharmaceuticals shares in Q1 2014, an estimated $596K.
  • Vertex Pharmaceuticals made up 0.02% of F&C Asset Management's portfolio in Q1 2014, its #477 holding.
  • F&C Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 3 quarters since.
  • 395 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2014.

Based on F&C Asset Management's 13F filing for Q1 2014, filed 14 May 2014.